You are here: Industry Insights > DCGI

News List

CDSCO asks drug controllers to take measures against black marketing of remdesivir expresspharma
July 08, 2020
Reportedly, the drug is being sold at exorbitant prices ranging between Rs 15,000 to Rs 60,000.
Mylan to launch DESREM at Rs 4800 per vial expresspharma
July 07, 2020
Mylan will manufacture remdesivir in India at its injectables facilities, which also make product for the US.
Astrazeneca’s Dapagliflozin gets DCGI nod for treatment of heart failure expresspharma
July 06, 2020
Dapagliflozin (Forxiga) is an SGLT-2 inhibitor that can reduce the risk of cardiovascular death and hospitalisation for heart failure in patients with HFrEF.
Zydus Cadila gets DCGI approval for human clinical trials of COVID-19 vaccine expresspharma
July 03, 2020
The assent for human trials was given after the company submitted data of clinical trial on animals to the DCGI, in which the vaccine candidate was found to be successful with respect to safety and immunogenicity.
First COVID-19 vaccine clinical trial approved in India europeanpharmaceuticalreview
July 01, 2020
Indian authorities have given the green light to test Bharat Biotech’s COVID-19 vaccine in Phase I and Phase II clinical trials.
COVAXIN from Bharat Biotech gets DCGI approval for Phase I & II Human Clinical Trials expresspharma
June 30, 2020
The human trials of this vaccine candidate for COVID-19, indigenously developed in collaboration with ICMR-NIV, will start across India in July 2020.
Umifenovir gets DCGI nod for Phase III clinical trial against COVID-19 expresspharma
June 19, 2020
CSIR-CDRI has developed the process technology for Umifenovir and licensed the process technology for manufacturing and marketing of the drug to Medizest Pharmaceuticals, Goa, which has already received test license from DCGI.
Sun Pharma initiates Phase II clinical trial on AQCH as potential treatment for COVID-19 expresspharma
June 08, 2020
AQCH is the first phytopharmaceutical drug approved for clinical trial by DCGI for COVID-19 and has shown anti-SARS-CoV-2 effects in in-vitro studies.
Sun Pharma gets DCGI nod for clinical trial with Nafamostat in COVID-19 patients expresspharma
June 01, 2020
Nafamostat is identified as a potential candidate for COVID-19 patients by scientists at the University of Tokyo and Leibniz Institute for Primate Research, Germany.
Biocon Biologics gets DCGI approval for emergency use of CytoSorb to treat critical COVID-19 patient expresspharma
May 28, 2020
Biocon announced that its subsidiary Biocon Biologics has received the Drugs Controller General of India’s (DCGI) approval for an extracorporeal blood purification (EBP) device CytoSorb.

Previous page 1 2 3 4 5 6 7 8 9 10 Next page